09/19/23 8:00 AMNasdaq : ELOX offeringlow floatEloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesEloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of itsRHEA-AIneutral
09/18/23 7:00 AMNasdaq : ELOX clinical triallow floatEloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeHighly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans All three patients treated with ELX-02 showed a visual improvement in podocyte foot process effacementRHEA-AIneutral
09/07/23 9:00 AMNasdaq : ELOX low floatEloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations Rebound in average UPCR 3-months post treatment provides further evidence that proteinuria remission in one out of three patientsRHEA-AIpositive
08/14/23 8:30 AMNasdaq : ELOX earningslow floatEloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business UpdateAnnounced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy, demonstrating the disease-modifying effect of ELX-02 Announced achievement of remission in oneRHEA-AIneutral
08/14/23 8:00 AMNasdaq : ELOX clinical triallow floatEloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeAll three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02 Podocyte foot process effacement is a hallmark of AlportRHEA-AIneutral
08/03/23 9:26 AMNasdaq : ELOX low floatEloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing RequirementEloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq StockRHEA-AIpositive
07/10/23 9:00 AMNasdaq : ELOX low floatEloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic BenefitPublication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer” published in Cancer Research Communications Results suggest that MYC overexpressing cancers can be targeted by exploiting ribosomeRHEA-AIneutral
06/28/23 9:00 AMNasdaq : ELOX clinical triallow floatEloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02Alport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in COL4A and patients have significant unmet medical needs, with no disease modifying treatments currently available Eloxx announced additional results from its Phase 2 ELX-02 trial showing the patientRHEA-AIneutral
06/21/23 1:30 PMNasdaq : ELOX conferenceslow floatEloxx Pharmaceuticals to Host Investor and Analyst Call on Alport SyndromeRHEA-AIneutral
06/21/23 9:00 AMNasdaq : ELOX low floatEloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA CongressData from RaDaR natural history study indicates that Alport syndrome patients with autosomal recessive COL4A4 mutations have severest disease, with a more rapid progression to kidney failure Patient that achieved remission in Eloxx Phase 2 trial had autosomal recessive COL4A4 nonsense mutationRHEA-AIneutral